TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10322818

Group type: EXPERIMENTAL
Intervention: IKPA tablets and inhalated BDP
Number of subjects: 57

Group type: COMPARATOR
Intervention: Inhalated BDP singly
Number of subjects: 57
Study: 8215734

Group type: EXPERIMENTAL
Intervention: High-risk group (identified by predictive model)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-risk group (identified by predictive model)
Number of subjects: 60
Study: 3469936

Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Number of subjects: 144

Group type: COMPARATOR
Intervention: Intramuscular methotrexate
Number of subjects: 144
Study: 29773516

Group type: EXPERIMENTAL
Intervention: Lymphoedema management package including instructions for foot hygiene, skin care, bandaging, exercises, and use of socks and shoes, supported by lay Community Podoconiosis Agents at monthly meetings.
Number of subjects: 696

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 696
Study: 27073044

Group type: EXPERIMENTAL
Intervention: Topical liposomal azithromycin administered twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (glucantime) administered weekly with a volume of 0.5-2 cm3 into each lesion
Number of subjects: 66
Study: 24186676

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 22342850

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy with aspirin and clopidogrel
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Triple therapy with OAC, aspirin, and clopidogrel
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: OAC plus aspirin
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: OAC with either 1 or 2 antiplatelet agents
Number of subjects: 632

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 632
Study: 20039868

Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia in conjunction with general anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 60
Study: 18578172

Group type: EXPERIMENTAL
Intervention: VivaStyle Paint On Plus without VivaSens (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: VivaStyle Paint On Plus after a single application of VivaSens (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but inferred as Group A)
Number of subjects: 80
Study: 15290154

Group type: EXPERIMENTAL
Intervention: Anecortave Acetate for Depot Suspension (3, 15 and 30 mg)
Number of subjects: 128
Study: 11821495

Group type: EXPERIMENTAL
Intervention: Handwarming biofeedback (HWB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Handcooling (HCB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 36
Study: 10687569

Group type: EXPERIMENTAL
Intervention: Knee-chest position for 15 minutes three times a day for one week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no postural management)
Number of subjects: 100
Study: 7492378

Group type: EXPERIMENTAL
Intervention: Surgery for cure followed by postoperative chemotherapy (CAV - cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 183
Study: 2182696

Group type: EXPERIMENTAL
Intervention: 250 mg sustained-release theophylline (morning and evening)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 mg sustained-release theophylline (two capsules morning and evening)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (two capsules morning and evening)
Number of subjects: 12
Study: 1096539

Group type: EXPERIMENTAL
Intervention: Unilateral ECT treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bilateral ECT treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Unilateral and Bilateral)
Number of subjects: 100
Study: 30475074

Group type: EXPERIMENTAL
Intervention: Positive feedback group (participants told their memory performance was better than peers)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Neutral feedback group (participants told their memory performance was equivalent to peers)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 203
Study: 30969899

Group type: EXPERIMENTAL
Intervention: brief vibration during contraction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: prolonged vibration for 20 min before contraction
Number of subjects: 24

Group type: COMPARATOR
Intervention: control
Number of subjects: 24
Study: 28482765

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT)
Number of subjects: 53454

Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 53454
Study: 25439114

Group type: EXPERIMENTAL
Intervention: Presence of a dog during venipuncture (EG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No dog present during venipuncture (CG)
Number of subjects: 50
Study: 23039824

Group type: EXPERIMENTAL
Intervention: Non-dippers with normal awake and asleep SBP and DBP means
Number of subjects: 3344

Group type: COMPARATOR
Intervention: Dippers with elevated ambulatory BP
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Non-dippers with elevated ambulatory BP
Number of subjects: 3344
Study: 22338468

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic treatment (PCT-group; n = 102)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard care (standard group; n = 103)
Number of subjects: 205
Study: 19444516

Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (group B)
Number of subjects: 40
Study: 16682147

Group type: EXPERIMENTAL
Intervention: Androgen suppression therapy (AST) administered at a PSA level of approximately 10 ng/mL
Number of subjects: 81
Study: 14745141

Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (ANP) administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study: 11401185

Group type: EXPERIMENTAL
Intervention: Participation in pharmacy practice-based research study
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pharmacy practice-based research
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Understanding pharmacists' opinions
Number of subjects: 87
Study: 9244964

Group type: EXPERIMENTAL
Intervention: NeyTumorin
Number of subjects: 0
Study: 7962387

Group type: EXPERIMENTAL
Intervention: Method A: incubation of spermatozoa with pentoxifylline (PTX) and 2‐deoxyadenosine (DOA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Method B: electroporation followed by incubation in medium with PTX
Number of subjects: 53

Group type: COMPARATOR
Intervention: Method C: no further treatment with the Percoll gradient
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: T6 medium containing 1.78 mM CaCl2.2H2O and final washing step in T6 medium containing 5.0 mM CaCl2.2H2O
Number of subjects: 53

Group type: COMPARATOR
Intervention: Earle's medium containing 1.78 mM CaCl2.2H2O
Number of subjects: 53
Study: 3297471

Group type: EXPERIMENTAL
Intervention: Insulin (0.15 unit/kg body weight)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 5
Study: 30625094

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 130
Study: 26809936

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Race
Number of subjects: 0
Study: 25710287

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg and PegIFN/RBV
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg and PegIFN/RBV
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 24 weeks of PegIFN/RBV
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 48 weeks of PegIFN/RBV
Number of subjects: 308
Study: 23676766

Group type: EXPERIMENTAL
Intervention: rESAT6
Number of subjects: 32

Group type: COMPARATOR
Intervention: BSA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.1 µg rESAT6
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5 µg rESAT6
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1 µg rESAT6
Number of subjects: 32
Study: 20951320

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor administration in poor responders
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Poor response to clopidogrel
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Poor response to aspirin
Number of subjects: 826

Group type: COMPARATOR
Intervention: Full responders
Number of subjects: 826
Study: 18394495

Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-Power Laser (LPL)
Number of subjects: 60
Study: 16945048

Group type: COMPARATOR
Intervention: Heparin flushes (3 ml of porcine heparin 100 U/ml, 300 U per catheter lumen at least once/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lepirudin flushes (3 ml of lepirudin 100 microg/ml, 300 microg per catheter lumen at least once/day)
Number of subjects: 49
Study: 15292740

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU x d(‐1) alpha‐tocopherol)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 38
Study: 11315234

Group type: EXPERIMENTAL
Intervention: Tiludronate 50 mg/day
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg/day
Number of subjects: 2293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2293
Study: 9415907

Group type: EXPERIMENTAL
Intervention: Closed-suction, nonreinfusable wound drains
Number of subjects: 136
Study: 8216439

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray preparation (Isoket Spray) 2.5 mg per valve release
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference spray preparation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isosorbide-2-mononitrate (IS-2-MN) from test spray
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isosorbide-2-mononitrate (IS-2-MN) from reference spray
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) from test spray
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate (IS-5-MN) from reference spray
Number of subjects: 18
Study: 2890019

Group type: EXPERIMENTAL
Intervention: Post-treatment Campylobacter pylori status
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Culture positive for Campylobacter pylori
Number of subjects: 39

Group type: COMPARATOR
Intervention: Culture negative for Campylobacter pylori
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Recurrence of Campylobacter pylori after apparent eradication
Number of subjects: 39

Group type: COMPARATOR
Intervention: No recurrence of Campylobacter pylori
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Recurrence of Campylobacter pylori
Number of subjects: 39
Study: 31331265

Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 28380313

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication (CLM) during endocrine therapy
Number of subjects: 8010
Study: 25723719

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) with either 50% or 65% carbohydrate (CHO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Refeeding (RF) with low or high glycaemic index CHO
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weight re-gain
Number of subjects: 32
Study: 23349298

Group type: EXPERIMENTAL
Intervention: Creatine (CM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 21209140

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist service (medication reviews, feedback to physicians, drug treatment discussions, medication reports)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Intervention patients who received the intervention
Number of subjects: 345
Study: 19128534

Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-tasking training program (5 weeks, twice-daily practice)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-tasking training program
Number of subjects: 19
Study: 17134890

Group type: EXPERIMENTAL
Intervention: Aprepitant/ondansetron/dexamethasone
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Ondansetron/dexamethasone
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Aprepitant-based regimen
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 1032
Study: 15607090

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 3D MR voiding urethrography (CE 3D MRVU)
Number of subjects: 23
Study: 11276541

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention delivered by nurse facilitators over 18 months (July 1997 to December 1998)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention delivered by nurse facilitators
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 9505772

Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Late extubation
Number of subjects: 85
Study: 7839480

Group type: EXPERIMENTAL
Intervention: Active laser treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 89
Study: 2905808

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.02 mg/kg) followed by Ro 15‐1788 (0.03 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ro 15‐1788 (0.03 mg/kg) alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo followed by Ro 15‐1788
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.02 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ro 15‐1788 (0.03 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lormetazepam group prior to administration
Number of subjects: 10
Study: 30193927

Group type: EXPERIMENTAL
Intervention: LE gel 2 times a day
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: LE gel 3 times a day
Number of subjects: 514

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 514
Study: 27349272

Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine (5 µg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intrathecal morphine (100 µg)
Number of subjects: 120
Study: 24141709

Group type: EXPERIMENTAL
Intervention: Early Risers conduct problems prevention program
Number of subjects: 223
Study: 22537244

Group type: EXPERIMENTAL
Intervention: 30 g of chocolate (70% cocoa) daily (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 90
Study: 19915454

Group type: EXPERIMENTAL
Intervention: Quetiapine 50 mg every 12 hrs, increased as needed up to 200 mg every 12 hrs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18279409

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (100,000 IU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15751775

Group type: EXPERIMENTAL
Intervention: tenofovir/didanosine/efavirenz (arm A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: tenofovir/didanosine/efavirenz without lopinavir/r (arm B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Baseline characteristics of VF patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resistance mutations detected
Number of subjects: 36
Study: 12913375

Group type: EXPERIMENTAL
Intervention: Clinical environment (bedside) for learning and recall
Number of subjects: 63

Group type: COMPARATOR
Intervention: Educational environment (classroom) for learning and recall
Number of subjects: 63
Study: 10947303

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg/day for an average of 10 days)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Atgam (15 mg/kg/day for an average of 9.7 days)
Number of subjects: 163
Study: 8707759

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusion therapy
Number of subjects: 0
Study: 2004962

Group type: EXPERIMENTAL
Intervention: Simulated with oral contrast
Number of subjects: 115

Group type: COMPARATOR
Intervention: Simulated without oral contrast
Number of subjects: 115
Study: 6364442

Group type: EXPERIMENTAL
Intervention: Active ioniser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo ioniser
Number of subjects: 20

Group type: COMPARATOR
Intervention: No ioniser
Number of subjects: 20
Study: 30935524

Group type: EXPERIMENTAL
Intervention: Melatonin (high dose [24 mg], sustained-release formulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29454227

Group type: EXPERIMENTAL
Intervention: l-Carnitine 2g/day for one week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment with placebo
Number of subjects: 40
Study: 27543374

Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE) based RV global longitudinal strain (GLS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RV GLS cutoff value of ‐18%
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional echocardiographic function parameters
Number of subjects: 57
Study: 25070319

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.06 to 0.24 mg/kg/d) for 6 months to 11 years
Number of subjects: 31
Study: 23278572

Group type: EXPERIMENTAL
Intervention: 10 mg EN101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg EN101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg EN101
Number of subjects: 0
Study: 20399588

Group type: EXPERIMENTAL
Intervention: sarpogrelate
Number of subjects: 22
Study: 19060999

Group type: EXPERIMENTAL
Intervention: T3-T4 sympathectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: T4 sympathectomy
Number of subjects: 64
Study: 15716161

Group type: EXPERIMENTAL
Intervention: Narrative joke subtest
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cartoon subtest
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Covarying comprehension of nonliteral language and proverbs
Number of subjects: 16
Study: 14504455

Group type: EXPERIMENTAL
Intervention: Men with melancholic depression (N1 scale)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Women with melancholic depression (N1 scale)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Overall severity and symptomatology of depression
Number of subjects: 930
Study: 10564628

Group type: EXPERIMENTAL
Intervention: Educational and skills-training program emphasizing double gloving
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (third-year students)
Number of subjects: 149
Study: 8732611

Group type: EXPERIMENTAL
Intervention: Intravenous thiopentone (group I)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Halothane inhalation (group II)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Rectal methohexitone (group III)
Number of subjects: 92
Study: 2057023

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Invasive cardiac procedures
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Bypass surgery among those who underwent catheterization
Number of subjects: 2231
Study: 6214438

Group type: EXPERIMENTAL
Intervention: 0.125 mg desogestrel + 0.050 mg ethinylestradiol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both contraceptive combinations
Number of subjects: 16
Study: 31357887

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ezetimibe alone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Bempedoic acid alone
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination
Number of subjects: 301
Study: 31298268

Group type: EXPERIMENTAL
Intervention: Storytelling video intervention (n = 54)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Written information (comparison group, n = 50)
Number of subjects: 104
Study: 28618568

Group type: EXPERIMENTAL
Intervention: Power-law distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Γ distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: δ-function distribution
Number of subjects: 0
Study: 26816332

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24692082

Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole (LET) administered for 24-28 weeks before surgery
Number of subjects: 503
Study: 22207299

Group type: EXPERIMENTAL
Intervention: Cerecyte coils
Number of subjects: 500

Group type: COMPARATOR
Intervention: bare platinum coils
Number of subjects: 500
Study: 20175427

Group type: EXPERIMENTAL
Intervention: Accumulating short bouts of running at 70% of maximum oxygen uptake in six 5‐min bouts with 85 min rest between runs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (resting throughout the day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both exercise and control trials
Number of subjects: 10
Study: 17471547

Group type: EXPERIMENTAL
Intervention: Creatine supplements (20 gm/day for 8 days, then 3 gm/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Creatine supplements
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 15239231

Group type: EXPERIMENTAL
Intervention: Bipolar scissors
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 30
Study: 17661604

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion for 6 months
Number of subjects: 89
Study: 10822073

Group type: COMPARATOR
Intervention: Heparin and aspirin (group 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Argatroban and aspirin (group 2)
Number of subjects: 27
Study: 8867254

Group type: EXPERIMENTAL
Intervention: Experimental pain stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 0